Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Larimar Therapeutics, Inc. (LRMR)

4.3200 -0.0400 (-0.92%)
At close: August 17 at 4:00:01 PM EDT
4.3871 +0.0671 (+1.55%)
After hours: August 17 at 7:34:07 PM EDT
Trade LRMR on Coinbase
Chart Range Bar
Loading chart for LRMR
Chart does not reflect overnight price.
  • Previous Close 4.3600
  • Open 4.3200
  • Bid 2.9500 x 200
  • Ask 5.2900 x 200
  • Day's Range 4.3000 - 4.4199
  • 52 Week Range 2.7150 - 6.4200
  • Volume 874,315
  • Avg. Volume 2,056,843
  • Market Cap (intraday) 448.774M
  • Beta (5Y Monthly) 0.75
  • PE Ratio (TTM) --
  • EPS (TTM) -2.0100
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 14.30

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

www.larimartx.com

71

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LRMR
13.39%
S&P 500 (^GSPC)
13.14%

1-Year Return

LRMR
7.73%
S&P 500 (^GSPC)
20.08%

3-Year Return

LRMR
9.37%
S&P 500 (^GSPC)
77.22%

5-Year Return

LRMR
68.07%
S&P 500 (^GSPC)
74.12%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -32.78M

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-60M
-40M
-20M
0

Analyst Insights

View More

Analyst Price Targets

5.00
14.30 Average
4.3200 Current
26.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/5/2026
Analyst Wedbush
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 12 -> 11

Statistics

View More

Valuation Measures

Annual
As of 8/14/2026
  • Market Cap

    453.45M

  • Enterprise Value

    302.14M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.56

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -70.96%

  • Return on Equity (ttm)

    -139.63%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -172.6M

  • Diluted EPS (ttm)

    -2.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    156.27M

  • Total Debt/Equity (mrq)

    3.89%

  • Levered Free Cash Flow (ttm)

    -94.18M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

4.3200 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: